568594-83-2

Upstream product

• 288-36-8 1,2,3-triazole 
• 40877-19-8 4-chloro-1-(4-methoxyphenyl)butan-1-one 
• 100-66-3 methoxybenzene 
• 108-05-4 vinyl acetate 
• 189079-75-2 4-azido-1-(4-methoxyphenyl)butan-1-one 

Downstream Products

• 391202-16-7 1-(4-(4-methoxyphenyl)butyl)-1H-1,2,3-triazole 
• 366016-82-2 4-[4-(1H-1,2,3-triazole-1-yl)butyl]phenol 

Relevant academic research and scientific papers

A Facile Total Synthesis of Mubritinib

A five-step, practical, and concise total synthesis of mubritinib is described. The synthesis utilized Friedel-Crafts acylation, click reaction, reduction, and demethylation for the construction of the triazole ring system as key steps. Another important feature of this synthesis is the Bredereck oxazole synthesis. The main advantages of this process are the improved yield and decreased number of reaction steps, which paves the way for the industrial-scale synthesis of mubritinib.

Synthesis method of mubritinib triazole intermediate

The invention discloses a method for synthesizing a mubritinib triazole intermediate by taking propiolic acid as a raw material through a Click reaction. The method comprises the following steps: 1, taking anisole as a raw material, and carrying out a Friedel-Crafts acylation reaction with 4-chlorobutyryl chloride to obtain gamma-chloro-4-methoxyphenylbutanone, 2, enabling the gamma-chloro-4-methoxyphenylbutanone to react with sodium azide, propiolic acid, a copper catalyst, sodium ascorbate, an alkali and a solvent, so as to obtain 1-(4-methoxyphenyl)-4-(1H-1, 2, 3-triazole-1-yl)-1-butanone,3, reducing carbonyl into methylene by 1-(4-methoxyphenyl)-4-(1H-1, 2, 3-triazole-1-yl)-1-butanone in a trifluoroacetic acid/triethylsilane system, and 4, carrying out demethylation on the 1-[4-(4-methoxyphenyl)butyl]-1H-1, 2, 3-triazole by using 40% hydrobromic acid to obtain the mubritinib intermediate 4-[4-(1H-1, 2, 3-triazole-1-yl)butyl]phenol. The method greatly shortens the reaction path, and has the advantages of accessible raw materials, mild reaction conditions, high yield and the like, and is simple to operate.

HETEROCYCLIC MITOCHONDRIAL ACTIVITY INHIBITORS AND USES THEREOF

Heterocyclic compounds of Formula (I) and pharmaceutically acceptable salt thereof are disclosed. The use of such heterocyclic compounds and pharmaceutically acceptable salt thereof for the treatment of cancers, and more particularly cancers sensitive to mitochondrial activity inhibition and increased reactive oxygen species (ROS) levels, is also disclosed. Such cancers include acute myeloid leukemia (AML), preferably AML characterized by certain features, such as high level of expression of one or more Homeobox (HOX)-network genes, high and/or low expression of specific genes, the presence of one or more cytogenetic or molecular risk factors such as intermediate cytogenetic risk, Normal Karyotype (A/K), mutated NPM1, mutated CEBPA, mutated FLT3, mutated DNMT3A, mutated TET2, mutated IDH1, mutated IDH2, mutated RUNX1, mutated WT1, mutated SRSF2, intermediate cytogenetic risk with abnormal karyotype (intern(abnK)), trisomy 8 (+8) and/or abnormal chromosome (5/7), and/or a high leukemic stem cell (LSC) frequency.

2-HETEROCYCLYL-5-PHENOXYMETHYLPYRIDINE DERIVATIVES AS ANTICANCER AGENTS

Objects of the present invention are the compounds of formula I their pharmaceutically acceptable salts, enantiomeric forms, diastereoisomers and racemates, the preparation of the above-mentioned compounds, medicaments containing them and their manufactur

1,2,3 -TRIAZOLE DERIVATIVES AS RECEPTOR TYROSINE KINASE INHITORS

Objects of the present invention are the compounds of formula (I) their pharmaceutically acceptable salts, enantiomeric forms, diastereoisomers and racemates, the preparation of the above-mentioned compounds, medicaments containing them and their manufacture, as well as the use of the above-mentioned compounds in the control or prevention of illnesses such as cancer.